Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.

Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC).

Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0.

2.

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.

García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC).

Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16.

PMID:
30446802
3.

Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors.

Bermejo M, Ambrosioni J, Bautista G, Climent N, Mateos E, Rovira C, Rodríguez-Mora S, López-Huertas MR, García-Gutiérrez V, Steegmann JL, Duarte R, Cervantes F, Plana M, Miró JM, Alcamí J, Coiras M.

Biochem Pharmacol. 2018 Oct;156:248-264. doi: 10.1016/j.bcp.2018.08.031. Epub 2018 Aug 22.

PMID:
30142322
4.

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutierrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JÁ, Sánchez-Guijo F, Martínez-García AB, Villalón L, Conesa-García V, Rodriguez A, Casado F, Garcia-Gonzalez X, Sáez Perdomo MN, Baños Ú, Steegmann JL; CML Spanish Group (GELMC).

Ann Hematol. 2018 Nov;97(11):2089-2098. doi: 10.1007/s00277-018-3413-7. Epub 2018 Jun 28.

PMID:
29955943
5.

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF.

J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188. doi: 10.1007/s00432-017-2532-1.

6.

Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner.

Kreutzman A, Colom-Fernández B, Jiménez AM, Ilander M, Cuesta-Mateos C, Pérez-García Y, Arévalo CD, Brück O, Hakanen H, Saarela J, Ortega-Carrión A, de Rosendo A, Juanes-García A, Steegmann JL, Mustjoki S, Vicente-Manzanares M, Muñoz-Calleja C.

Clin Cancer Res. 2017 Nov 1;23(21):6697-6707. doi: 10.1158/1078-0432.CCR-16-0667. Epub 2017 Aug 18.

7.

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.

Alonso-Dominguez JM, Casado LF, Anguita E, Gomez-Casares MT, Buño I, Ferrer-Marín F, Arenas A, Del Orbe R, Ayala R, Llamas P, Salgado RN, Osorio S, Sanchez-Godoy P, Burgaleta C, Mahíllo-Fernández I, Garcia-Gutierrez V, Steegmann JL, Martinez-Lopez J.

PLoS One. 2017 Jul 13;12(7):e0181366. doi: 10.1371/journal.pone.0181366. eCollection 2017.

8.

An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF.

J Cancer Res Clin Oncol. 2017 Oct;143(10):2059-2066. doi: 10.1007/s00432-017-2445-z. Epub 2017 May 27. Erratum in: J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188.

9.

Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.

Wojnicz A, Colom-Fernández B, Steegmann JL, Muñoz-Calleja C, Abad-Santos F, Ruiz-Nuño A.

Ther Drug Monit. 2017 Jun;39(3):252-262. doi: 10.1097/FTD.0000000000000406.

PMID:
28490048
10.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

11.

A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.

García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, Collado R, Ramírez MJ, Ibáñez F, Martín ML, Rodríguez-Gambarte JD, Martínez-Laperche C, Gómez M, Fiallo DV, Redondo S, Rodríguez A, Ruiz-Nuño C, Steegmann JL, Jiménez-Velasco A; Spanish Group of Chronic Myeloid Leukemia (GELMC).

PLoS One. 2017 Mar 9;12(3):e0173532. doi: 10.1371/journal.pone.0173532. eCollection 2017.

12.

Reply to Constance et al.

Steegmann JL, Baccarani M, Clark RE.

Leukemia. 2017 Mar;31(3):772-773. doi: 10.1038/leu.2016.337. Epub 2016 Dec 6. No abstract available.

PMID:
27922619
13.

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.

Cervantes F, Correa JG, Pérez I, García-Gutiérrez V, Redondo S, Colomer D, Jiménez-Velasco A, Steegmann JL, Sánchez-Guijo F, Ferrer-Marín F, Pereira A, Osorio S; CML Spanish Group (GELMC).

Ann Hematol. 2017 Jan;96(1):81-85. doi: 10.1007/s00277-016-2839-z. Epub 2016 Oct 8.

PMID:
27717993
14.

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martínez C, Albors M, García F, Burgaleta C, Besses C; Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas.

Haematologica. 2017 Jan;102(1):103-109. doi: 10.3324/haematol.2016.152769. Epub 2016 Sep 29.

15.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE.

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28. Review.

16.

Chronic myeloid leukaemia in Spain: Its presentation characteristics have changed. Spanish section of the EUTOS population-based registry.

Osorio S, Casado LF, Giraldo P, Maestro B, Andrade M, Redondo S, García-Gutiérrez V, Ayala R, Garcia N, Steegmann JL.

Rev Clin Esp. 2016 Aug-Sep;216(6):293-300. doi: 10.1016/j.rce.2016.03.001. Epub 2016 Apr 6. English, Spanish.

PMID:
27061504
17.

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials.

le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE.

Leukemia. 2016 Jul;30(7):1593-6. doi: 10.1038/leu.2015.352. Epub 2015 Dec 21. No abstract available.

18.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-Jedrzejczak W, Rea D, Coriu D, Brümmendorf TH, Porkka K, Saglio G, Gastl G, Müller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L, Mahon FX, Baccarani M, Giles FJ.

Leukemia. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270. Epub 2015 Oct 6.

19.

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R.

Leukemia. 2015 Jun;29(6):1336-43. doi: 10.1038/leu.2015.73. Epub 2015 Mar 18.

PMID:
25783795
20.

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.

Casado LF, García-Gutiérrez JV, Massagué I, Giraldo P, Pérez-Encinas M, de Paz R, Martínez-López J, Bautista G, Osorio S, Requena MJ, Palomera L, Peñarrubia MJ, Calle C, Hernández-Rivas JÁ, Burgaleta C, Maestro B, García-Ormeña N, Steegmann JL.

Cancer Med. 2015 Jul;4(7):995-1002. doi: 10.1002/cam4.440. Epub 2015 Mar 10.

21.

Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.

García-Gutiérrez V, Martinez-Trillos A, Lopez Lorenzo JL, Bautista G, Martin Mateos ML, Alvarez-Larrán A, Iglesias Pérez A, Romo Collado A, Fernandez A, Portero A, Cuevas B, Ruiz C, Romero E, Ortega F, Mata I, Tallón J, García Garay Mdel C, Ramirez Sánchez MJ, de Las Heras N, Giraldo P, Bobillo S, Guinea JM, Deben G, Valencia S, Sebrango A, Boqué C, Maestro B, Steegmann JL.

Am J Hematol. 2015 May;90(5):429-33. doi: 10.1002/ajh.23973. Epub 2015 Mar 30.

22.

Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.

Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA, Wallis NT.

Am J Hematol. 2015 Apr;90(4):E66-72. doi: 10.1002/ajh.23938. Epub 2015 Jan 30.

23.

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

García-Gutiérrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, Perez-Encinas M, Moreno Romero MV, Suñol PB, Sola Garcia R, De Paz R, Ramirez Sanchez MJ, Osorio S, Mata Vazquez MI, Martinez López J, Sastre JL, Portero Mde L, Bautista G, Duran Nieto MS, Giraldo P, Jimenez Jambrina M, Burgaleta C, Ruiz Aredondo J, Peñarrubia MJ, Requena MJ, Fernández Valle Mdel C, Calle C, Paz Coll A, Hernández-Rivas JÁ, Franco Osorio R, Cano P, Tallón Pérez D, Fernández de la Mata M, Garrido PL, Steegmann JL.

Am J Hematol. 2014 Nov;89(11):E206-11. doi: 10.1002/ajh.23816. Epub 2014 Aug 27.

24.

Paroxysmal nocturnal hemoglobinuria: a single Spanish center's experience over the last 40 yr.

Muñoz-Linares C, Ojeda E, Forés R, Pastrana M, Cabero M, Morillo D, Bautista G, Baños I, Monteserín C, Bravo P, Jaro E, Cedena T, Steegmann JL, Villegas A, Cabrera JR.

Eur J Haematol. 2014 Oct;93(4):309-19. doi: 10.1111/ejh.12346. Epub 2014 May 13.

25.

Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study.

Llamas-Velasco M, Fraga J, Kutzner H, Steegmann JL, García-Diez A, Requena L.

J Cutan Pathol. 2014 May;41(5):417-26. doi: 10.1111/cup.12298. Epub 2014 Feb 26.

PMID:
24467724
26.

Multiple eruptive dermatofibromas related to imatinib treatment.

Llamas-Velasco M, Fraga J, Solano-López GE, Steegmann JL, García Diez A, Requena L.

J Eur Acad Dermatol Venereol. 2014 Jul;28(7):979-81. doi: 10.1111/jdv.12328. Epub 2013 Dec 10. No abstract available.

PMID:
24321053
27.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A.

Blood. 2014 Jan 23;123(4):494-500. doi: 10.1182/blood-2013-06-511592. Epub 2013 Dec 5.

28.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R.

Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26. Review.

29.

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.

Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M.

Leukemia. 2013 Oct;27(10):2016-22. doi: 10.1038/leu.2013.171. Epub 2013 Jun 11.

PMID:
23752173
30.

Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.

Llamas-Velasco M, Steegmann JL, Carrascosa R, Fraga J, García Diez A, Requena L.

Am J Dermatopathol. 2014 Jul;36(7):592-3. doi: 10.1097/DAD.0b013e31828cf3b7.

PMID:
23612033
31.

Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.

Steegmann JL, Sánchez Torres JM, Colomer R, Vaz Á, López J, Jalón I, Provencio M, González-Martín A, Pérez M.

Clin Transl Oncol. 2013 Jun;15(6):477-83. doi: 10.1007/s12094-012-0953-5. Epub 2012 Dec 19.

32.

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M; ESMO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii72-7. No abstract available.

PMID:
22997458
33.

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.

Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G.

Leuk Lymphoma. 2012 Dec;53(12):2351-61. doi: 10.3109/10428194.2012.695779. Epub 2012 Jun 18. Review.

PMID:
22616642
34.

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.

Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R.

Blood. 2012 Jun 21;119(25):5963-71. doi: 10.1182/blood-2011-10-383711. Epub 2012 Apr 16.

35.

Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.

Cuesta-Domínguez Á, Ortega M, Ormazábal C, Santos-Roncero M, Galán-Díez M, Steegmann JL, Figuera Á, Arranz E, Vizmanos JL, Bueren JA, Río P, Fernández-Ruiz E.

PLoS One. 2012;7(2):e32451. doi: 10.1371/journal.pone.0032451. Epub 2012 Feb 27.

36.

Pneumocystis jirovecii pneumonia as first manifestation of late relapse angioimmunoblastic T-cell lymphoma.

García-Noblejas A, Velasco A, García-León N, Cananta-Ortiz J, Steegmann JL.

Leuk Res. 2011 Sep;35(9):e143-4. doi: 10.1016/j.leukres.2011.04.019. Epub 2011 May 13. No abstract available.

PMID:
21570116
37.

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.

Giles FJ, Rosti G, Beris P, Clark RE, le Coutre P, Mahon FX, Steegmann JL, Valent P, Saglio G.

Expert Rev Hematol. 2010 Dec;3(6):665-73. doi: 10.1586/ehm.10.61. Epub 2010 Nov 9.

PMID:
21091142
38.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K.

Leukemia. 2009 Aug;23(8):1398-405. doi: 10.1038/leu.2009.46. Epub 2009 Mar 19.

PMID:
19295545
39.

PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.

Albajar M, Gutierrez P, Richard C, Rosa-Garrido M, Gómez-Casares MT, Steegmann JL, León J, Delgado MD.

Cancer Lett. 2008 Nov 8;270(2):328-36. doi: 10.1016/j.canlet.2008.05.024. Epub 2008 Jul 16.

40.

Intracerebral Hodgkin's lymphoma in a patient with human immunodeficiency virus.

García-Noblejas A, Nieto S, Liberal R, Cannata J, Steegmann JL, Fernàndez-Rañada JM, Arranz R.

Haematologica. 2007 Jun;92(6):e72-3.

41.
42.
43.

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.

Villuendas R, Steegmann JL, Pollán M, Tracey L, Granda A, Fernández-Ruiz E, Casado LF, Martínez J, Martínez P, Lombardía L, Villalón L, Odriozola J, Piris MA.

Leukemia. 2006 Jun;20(6):1047-54.

PMID:
16598311
44.

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.

Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J.

Haematologica. 2005 Mar;90(3):335-40.

45.

Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.

Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J, Osorio S, Villalón L, Camós M, García-Conde J, Odriozola J.

Haematologica. 2003 Oct;88(10):1117-22.

46.

A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.

Peñarrubia MJ, Odriozola J, González C, Massagué I, Miguel A, González San Miguel JD, Pérez Encinas M, Lavilla E, Giraldo MP, Casado LF, Ferrer S, Steegmann JL; Spanish Group on IFN and CML.

Ann Hematol. 2003 Dec;82(12):750-8. Epub 2003 Sep 27.

PMID:
14517691
47.

Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.

Steegmann JL, Moreno G, Aláez C, Osorio S, Granda A, de la Cámara R, Arranz E, Reino FG, Salvanés FR, Fernández-Rañada JM, Muñoz C.

Haematologica. 2003 Jul;88(7):762-8.

48.

High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha.

Steegmann JL, Requena MJ, Martín-Regueira P, De La Cámara R, Casado F, Salvanés FR, Fernández Rañada JM.

Am J Hematol. 2003 Mar;72(3):170-6.

49.

Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.

Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Thaler J, Steegmann JL; Collaborative CML Prognostic Factors Project Group.

Semin Hematol. 2003 Jan;40(1):4-12. Review.

PMID:
12563607
50.

Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older.

de la Cámara R, Alonso A, Steegmann JL, Arranz R, Granados E, Rodríguez-Macías G, Sanz-Rodríguez C, de Soria VG, Figuera A, Fernández-Rañada JM.

Haematologica. 2002 Sep;87(9):965-72.

Supplemental Content

Loading ...
Support Center